Rimonabant
- TRADE NAME: Acomplia (Sanofi-Aventis)
- INDICATIONS: Obesity
- CLASS: CB1 Cannabinoid receptor antagonist
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Ritonavir, Telithromycin
PREGNANCY CATEGORY: N/A
This drug has been withdrawn.
Please login to see the rest of this drug profile
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric